a huge fortnight coming, page-7

And both companies are funding highly potential phase 3 trials after very exciting phase 2 results.

Acl have been fumbling the ball, with investor expectations.

POH have really put a lot of hard work in, to fix this area. Where they were weak.

Perception is everything here.

As Kwaidan has previously posted doe ACL have any market savvy executives.

POH brought one in to fix their problem.

ACL could copy this strategy.